Biotech company Guard Therapeutics has received conditional approval from Nasdaq Stockholm for continued listing of its shares on Nasdaq First North.
Guard Therapeutics, a Swedish biotech company, has received conditional approval from Nasdaq Stockholm. The approval concerns continued listing of the company's shares on Nasdaq First North.
The decision was announced on July 16, 2026. It allows the company to remain on the marketplace under certain conditions.